]>
IRCT20170608034390N6 IRCT 2020-05-06 Shahid Beheshti University of Medical Sciences Effect of Cabergoline on biochemical and anthropometric parameters of patients with prediabetes. Evaluating the Effect of Cabergoline on insulin resistance and anthropometric parameters in patients with Impaired fasting glucose and/or Impaired glucose tolerance, a randomized, blinded clinical trial. 2016-05-04 anticipated 98 Complete https://irct.ir/trial/26287 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balanced block randomization, Blinding description: In this study participants, healthcare providers, investigator, outcome assessors and data analyst and quality controller are blinded. 2-3 Impaired Glucose Tolerance/Impaired Fasting Glucos. Intervention 1: Intervention group: cabergoline 0.5 mg tablets twice weekly. Intervention 2: Control group: cabergoline 0.5 mg placebo tablets twice weekly. Yes - There is a plan to make this available What will be shared: The whole potential data is unpublished after being unidentifiable. When: Start the access period 6 month after pricing the result To whom: Researchers working in academic and industrial institutions. Conditions: It can be used to carry out research work. Where to obtain: Dr Hadi Esmaily, School of pharmacy, shahid beheshti university of medical sciences How to obtain: Sending request is available. Comments: Sending request is available.
public Hadi Esmaily
Shahid Beheshti School of Pharmacy, Vali Ars AVe
Tehran Iran (Islamic Republic of) 1991953381 +98 21 8887 3704 Esmaily_hadi@sbmu.ac.ir Shahid Beheshti University of Medical Sciences scientific Hadi Esmaily
Shahid Beheshti Pharmaceutical Faculty, Vali Ars AVe
tehran Iran (Islamic Republic of) 1991953381 +98 21 8887 3704 esmaily_hadi@sbmu.ac.ir Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) Patients with Impaired Fasting Glucose and/or Impaired Glucose Tolerance Adults (18-65 years) 20 years 65 years Both Severe hepatic failure (Child-Pugh scores of 10 or higher) History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders Hypersensitivity to ergot derivatives Uncontrolled hypertension Diabetes Pregnant Women Lactating Women Major psychiatric disorders Patients who are receiving medications which affect prolactin secretion Bulimia or/and anorexia nervosa R73.02 Impaired glucose tolerance (oral) Treatment - Drugs Placebo Intervention group: cabergoline 0.5 mg tablets twice weekly Control group: cabergoline 0.5 mg placebo tablets twice weekly Fasting Plasma Glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Autoanalyzer. 2h plasma glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: اتوآنالایزر. Hb A1c. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: HPLC. 2h Insulin. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: الایزا. Wheight. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Scale. Height. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter. Wrist circumference. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter. Shahid Beheshti University of Medical Sciences Approved 2013-10-15 Ethics Committee in Research Institute of Endocrine Sciences and Metabolism, Shahid Beheshti Univers Endocrinology and Metabolism Research Institute, No. 24, At the beginning of Parvaneh St., Yemen St., Velenjak St., Shahid Chamran Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)